-
Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)
-
Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
-
Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
-
Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program
-
MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines
-
Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada
-
Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary
-
Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary
-
Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary
-
Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary